2,6-Dimethyl-4-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethoxy]-nicotinic acid methyl ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-Dimethyl-4-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethoxy]-nicotinic acid methyl ester
• 英文别名: methyl 2,6-dimethyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methoxy]pyridine-3-carboxylate
• 化学式: C₂₃H₂₁N₅O₃
• 分子量: 415.4
• InChiKey: PHTZSKZKEGZCHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Process for the preparation of tetrazole derivatives
  申请人：ZENECA LIMITED

  公开号：EP0495626A1

  公开（公告）日：1992-07-22

  A compound of formula VI wherein Q is selected from (substituted) 4-quinolyloxy, (substituted) 4-pyridyloxy and substituted 1-imidazolyl; Y¹ is selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxy, halogeno, (1-4C)alkanoyl, trifluoromethyl, cyano and nitro; Y² is selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxy, halogeno, trifluoromethyl, cyano and nitro; and P¹ is an electron-deficient phenyl group or a pyridyl or pyrimidyl group, is reacted with a base selected from an alkali metal hydroxide, (1-12C)alkanolate, (1-12C)alkanethiolate, phenolate, thiophenolate and diphenylphosphide, wherein any phenyl ring of the latter three groups may optionally bear a (1-4C)alkyl, (1-4C)alkoxy or halogeno substituent; to give a compound of formula IV wherein Q, Y¹ and Y² have any of the meanings defined above. The compounds of formula IV are angiotensin II inhibitors.

  化合物VI的式子，其中Q选择自（取代的）4-喹诺氧基，（取代的）4-吡啶氧基和取代的1-咪唑基; Y¹选择自氢，（1-4C）烷基，（1-4C）烷氧基，卤素，（1-4C）酰基，三氟甲基，氰基和硝基; Y²选择自氢，（1-4C）烷基，（1-4C）烷氧基，卤素，三氟甲基，氰基和硝基; P¹是电子不足的苯基或吡啶基或嘧啶基，与从碱金属氢氧化物，（1-12C）烷基醇盐，（1-12C）烷硫醇盐，苯酚盐，硫苯酚盐和二苯基膦选择的碱基反应，其中后三个基团的任何苯环可以选择性地带有（1-4C）烷基，（1-4C）烷氧基或卤素取代基; 得到式子IV的化合物，其中Q，Y¹和Y²具有上述定义的任何含义。式子IV的化合物是血管紧张素II抑制剂。
• Pyridine derivatives
  申请人：ZENECA LIMITED

  公开号：EP0453210A2

  公开（公告）日：1991-10-23

  The invention concerns pharmaceutically useful novel compounds of the formula I, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.

  本发明涉及在医药上有用的式 I 新型化合物及其无毒盐，以及含有它们的药物组合物。这些新型化合物具有治疗高血压和充血性心力衰竭等疾病的价值。本发明还涉及新型化合物的生产工艺以及这些化合物在医疗中的用途。
• Boron compounds
  申请人：ZENECA LIMITED

  公开号：EP0495627A1

  公开（公告）日：1992-07-22

  The invention concerns novel boron compounds of the formula IV, in which Q, Y¹, G¹ and G² have the various meanings defined herein, and their acid and base addition salts. The said compounds are useful in the manufacture of certain quinoline, pyridine and imidazole derivatives which have angiotensin II inhibitory activity. The invention also provides novel processes for the production of the quinoline, pyridine and imidazole derivatives.

  本发明涉及式 IV 的新型硼化合物（其中 Q、Y¹、G¹ 和 G² 具有本文所定义的各种含义）及其酸和碱加成盐。上述化合物可用于制造某些具有血管紧张素 II 抑制活性的喹啉、吡啶和咪唑衍生物。本发明还提供了生产喹啉、吡啶和咪唑衍生物的新工艺。
• US5245035A
  申请人：——

  公开号：US5245035A

  公开（公告）日：1993-09-14
• US5294716A
  申请人：——

  公开号：US5294716A

  公开（公告）日：1994-03-15